spacer image
Skip Nav Skip to Search
Contact
spacer image
get adobe reader

Announcements
white mail envelope

Sign
up for Announcement alerts

October 2, 2014

NATIONAL TRANSPORTATION SAFETY BOARD (NTSB) ANNOUNCEMENT (click to view):  On September 23, 2014, the NTSB issued a Safety Recommendation highlighting the importance of licensed health care providers and pharmacists routinely discussing with patients the effect their diagnosed medical conditions or recommended drugs may have on their ability to safely operate a vehicle in any mode of transportation.

August 28, 2014

NOTICE OF HYDROCODONE RESCHEDULE EFFECTIVE OCTOBER 6, 2014 (click to view):  All products containing Hydrocodone will be rescheduled as a Schedule II (C-II) beginning October 6, 2014.  To make the transition easier, the Board, working with multiple agencies, has summarized the essential information pertaining to the change.  This summary is designed for the convenience of both pharmacists and practitioners and should be shared as necessary. Pharmacists should make an effort to share with all pharmacy staff.

August 27, 2014

DEA UPDATE & DRUG DIVERSION SEMINAR - OCTOBER 13, 2014 (click to view flyer):  

The Oklahoma State Board of Pharmacy is hosting a continuing education program in Oklahoma City aimed at helping pharmacists deter, detect and prevent prescription drug abuse.  The program includes lunch and is approved by the OSBP CE Committee for 3 hours of continuing education.  The seminar is provided without charge to pharmacists to further the Board’s mission of protecting the health, safety and welfare of the citizens of Oklahoma.

The seminar will be held on Monday, October 13, 2014 at the Oklahoma Sports Hall of Fame, 2nd Floor Events Center, 4040 N Lincoln Blvd, Oklahoma City.  Sign-In begins at 11:00 and Lunch will be served at 12:00 p.m.  The continuing education program will start immediately after at 1:00 p.m.

The Board has planned for 300 participants for the program, and is accepting reservations on a first-come basis.  Pharmacists should email pharmacy@pharmacy.ok.gov with the following information to reserve a spot:

  • Full Name
  • OK Pharmacy Board License #
  • NABP e-Profile ID #
  • Birth Month
  • Birth Day
  • E-mail
  • Daytime Phone

August 5, 2014

TRAMADOL UPDATE: Tramadol will become a federally controlled Schedule IV beginning August 18, 2014.  Though Tramadol has been a controlled substance in the State of Oklahoma since November 1, 2012, the DEA is requiring that pharmacies take an inventory of all Tramadol and Tramadol-containing products on AUGUST 18, 2014.  The inventory must be kept on file in the pharmacy.

August 5, 2014

Congratulations!  Eighty-six (86) pharmacists were issued an Oklahoma Doctor of Pharmacy license during the period from May - July 2014 (click here to view).

May 27, 2014

NOTICE OF PARENTERAL PERMIT & PHARMACIST-IN-CHARGE REQUIREMENTS FOR LICENSED NON-RESIDENT PHARMACIES (click to view Board memo) 

Beginning July 1, 2014 there will be a change in the licensing requirements for non-resident pharmacies licensed by the Board that are compounding sterile drug products.  If a licensed non-resident pharmacy is compounding sterile drug products, they must obtain an Oklahoma "Parenteral Permit" in addition to their pharmacy license.

Beginning January 1, 2015 all new and renewal non-resident pharmacy license applications that require a parenteral permit (i.e. pharmacies compounding sterile drug products) will also be required to have an Oklahoma license pharmacy manager or pharmacist-in-charge.

September 11, 2013

Band-Aids - Just a Cover-up! by Angela Wall.  This article is provided by the Oklahoma Bureau of Narcotics and promotes the importance of Oklahoma's Prescription Monitoring Program (PMP) and Health Care Professionals working together.

August 6, 2013

The 2013 Law Book is now available for viewing and download under "Rules".  This book contains the unofficial laws and rules pertaining to the practice of pharmacy as effective July 25, 2013.  Copies have not been printed but are available through the agency website.

November 1, 2012

Effective November 1, 2012, tramadol and all tramadol-containing products will be classified as Schedule IV in the State of Oklahoma.  Pharmacies are required to TAKE AN INVENTORY OF THEIR TRAMADOL PRODUCTS ON NOVEMBER 1ST AND KEEP IT WITH THEIR ANNUAL CDS INVENTORY (inventories do NOT have to be sent to the Board). Make sure that you start submitting all tramadol prescription information to the Prescription Monitoring Program (PMP) as required per OBNDD rules beginning November 1st as well.

Beginning November 1st:

  • All tramadol-containing prescriptions older than six (6) months will be expired.
  • All tramadol-containing prescriptions less than six (6) months old but with more than 5 refills already dispensed will be expired.
  • All tramadol-containing prescriptions less than six (6) months old but with up to 5 refills remaining should be valid for the remainder of the six (6) months period and up to the remaining but not to exceed the 5 refills on a controlled prescription.

The pharmacist may have to rewrite the prescriptions for filing purposes.  They need to be sure to reference them back properly to the original prescription number.

August 14, 2012

PSE questions & answers for pharmacies selling PSE. (click to view)

July 2, 2012

Letter to Pharmacies about PSE Changes (click to view).

December 14, 2011

In the near future, pharmacists who complete ACPE accredited CPE programs will NOT receive a printed CPE certificate from CPE providers.  To receive CPE credit, those pharmacists will first need to register and create an NABP e-Profile with CPE Monitor, if they have not done so already, and provide their unique e-Profile ID and date of birth (mmdd) to the ACPE-accredited CPE provider.  If pharmacists wish to receive credit for ACPE accredited programs, they must register at www.MyCPEmonitor.net for their unique e-Profile ID.  The ID number is a requirement of ACPE, not the Oklahoma State Board of Pharmacy. View CE Update for more information.

August 2, 2011

Summary of Standards for Drug Testing effective November 1, 2011 (click here to view).  To review full statute please go to 
http://www.oscn.net/applications/oscn/Search.asp?ftdb=STOKST40&quick=true.
[40 O.S. § § 551-565]

June 16, 2011

Pilot program approved with www.disposemymeds.org.  The Board has approved the establishment of a pilot program in conjunction with the National Community Pharmacists Association (NCPA) and the “disposemymeds.org” (DMM) program for the safe disposal of unused/unwanted/expired (UUE) medications. This pilot program will allow Oklahoma in-state licensed pharmacies to establish a drop-off location in their pharmacy for UUE medications, and then dispose of them through the DMM program. (click here to view further details)

January 24, 2011

Requirements for electronic transmission of controlled substance prescriptions.

October 6, 2010

DEA Policy Statement on Role of Agents in Communicating CS Prescriptions:
Drug Enforcement Administration (DEA) issued a statement of policy that clarifies the proper role of a duly authorized agent of a DEA-registered individual practitioner in communicating controlled substance (CS) prescription information to a pharmacy. The statement, published October 6, 2010, in the Federal Register, reminds health care providers that a prescription for a CS medication must be issued by a DEA-registered practitioner acting in the usual course of professional practice. Such a practitioner may authorize an agent to “perform a limited role in communicating such prescriptions to a pharmacy in order to make the prescription process more efficient,” and the guidance emphasizes that medical determinations to prescribe CS medications may be made by the practitioner only. The specific circumstances in which an agent may assist in communicating prescription information to a pharmacy are detailed and include:
♦♦ An authorized agent may prepare the prescription, based on the instructions of the prescribing practitioner, for the signature of that DEA-registered practitioner.
♦♦ For a Schedule III-V drug, an authorized agent may transmit a practitioner-signed prescription to a pharmacy via facsimile, or may communicate the prescription orally to a pharmacy on behalf of the practitioner.
♦♦ An authorized agent may transmit by facsimile a practitioner signed Schedule II prescription for a patient in a hospice or long-term care facility (LTCF) on behalf of the practitioner.
The guidance also makes clear that generally, Schedule II prescriptions may not be transmitted by facsimile and that hospice and LTCFs are exceptions. Further,Schedule II prescriptions may only be communicated orally by the DEA-registered practitioner and only in emergency situations. DEA stresses that the practitioner should decide who may act as his or her authorized agent and advises that such designation be established in writing. An example written agreement is included in the policy statement, along with additional guidance related to designating an authorized agent. DEA also notes that as electronic prescribing for CS is implemented and its use increases, the role of the agent in communicating CS prescriptions will likely be reduced over time. The DEA policy statement is available on the
Federal Register Web site at www.federalregister.gov/articles/2010/10/06/2010-25136/roleof-authorized-agents-in-communicating-controlled-substanceprescriptions-to-pharmacies.

July 2, 2009

EFFECTIVE IMMEDIATELY the following ID's are allowed in Oklahoma for PSE:

State Issued Driver's License
State Issued ID Card
Military ID
Passport

If, and only if, a patient has none of these types of ID, such as a nursing home patient, then you may use a social security number to submit for PSE and PMP.  For the purpose of accepting ID’s, please refer to the following definition:  “State” means any state, territory, or possession of the United States, the District of Columbia, or foreign nation.

Any questions concerning PSE requirements should be directed to the Oklahoma Bureau of Narcotics at 405-521-2885.

July 1, 2008 (updated May 4, 2009)

Advanced Practice Nurses with authority to prescribe C-III thru C-V controlled substances can prescribe up to 30 days supply. The 30 days supply may be a combination of the initial fill and a number of refills which adds up to the 30 days supply.  For example, a prescription for a 10 day supply could have up to 2 refills which would equal a 30 days supply.  This change is a result of a change in the Oklahoma regulations effective July 1, 2008.  [Note: Physician's Assistants may prescribe up to a 30 day supply as an individual prescription, but are not allowed to prescribe refills on controlled substances.]

September 15, 2008

Detailed information regarding tamper resistant requirements is available online from OHCA or by requesting a faxed copy from the OHCA Pharmacy Help Desk at 405-522-6205 option 4.

January 1, 2005

Oklahoma's Unused Prescription Drug Program became effective January 1, 2005.  Oklahoma Assisted Living Centers wishing to participate in the program may submit an Application for Donation Of Unused Prescription Drugs to the Board.  A list of the pharmacies participating in the program will be posted on this website.

 

Last Modified on 10/02/2014
Related Topics